RHÖN-KLINIKUM AG closed financial year 2025 with solid results, meeting its financial targets despite challenging health policy and economic conditions. The German hospital group reported treating 938,650 patients across its facilities, representing a 2.5% increase from the previous year's 912,965 patients. Group revenue reached €1,704.7 million, marking organic growth of 6.8% from €1,595.6 million in 2024.
The company maintained financial stability despite several challenges, including the end of legislative relief for higher energy prices and difficult cost structures in purchasing medical products and services, along with personnel expenses. EBITDA amounted to €105.9 million, slightly down from €110.8 million in 2024. Consolidated profit decreased to €36.3 million from €45.2 million, primarily due to higher depreciation and impairment of fixed assets as well as declining interest rates.
Dr. Stefan Stranz, member of the Board of Management, noted that the group's economic development remains solid and positive given the tense situation of hospitals and industry development in Germany. He emphasized the importance of cooperation within the corporate group with ASKLEPIOS as a key success factor in an environment characterized by medical progress, increasing demand for high-quality medical care, and growing economic pressure.
Throughout 2025, RHÖN-KLINIKUM AG launched further clinic development measures, adding new care offerings at all locations to expand outpatient and inpatient treatment. The two university locations in Gießen and Marburg combined their strengths in a joint breast center, setting a new standard in oncological care in Hesse. Dr. Gunther K. Weiß, another Board of Management member, stated that as a high-performing and integrated hospital group, they possess the necessary know-how and opportunities to actively shape changes for patient benefit.
The company's financial stability enables targeted and forward-looking implementation of large investments in medical high-tech. In 2025, investments included a new laboratory line in Giessen, new cardiac catheter technologies and a 3 Tesla magnetic resonance tomograph in Marburg, and a radiotherapy system for cancer treatment in Bad Berka. The group has opened a new chapter with photon technology, becoming the only hospital group with three photon counting computer tomographs of the latest generation in use, with further investments planned. The company publishes its financial reports and information on its corporate website at https://www.rhoen-klinikum-ag.com.
For 2026, the Group expects revenues of approximately €1.7 billion within a range of plus or minus 5%. EBITDA is projected to reach between €110 million and €125 million. Beyond financial metrics, RHÖN-KLINIKUM AG also considers non-financial performance indicators including number of cases and cost weights in company management, which are expected to see moderate increases compared to the previous year.
This forecast reflects heightened regulatory interference by the German legislator and political implementation of necessary hospital reform. The outlook remains subject to considerable uncertainties related to global crises resulting in higher prices and supply chain issues, along with potential further regulatory measures impacting the remuneration structure for medical services in 2026. The complete Annual Report 2025 is available through the company's online channels, including the original release published on https://www.newmediawire.com.
